News Focus
News Focus
Followers 142
Posts 23878
Boards Moderated 0
Alias Born 06/13/2011

Re: ORBAPU post# 370157

Friday, 02/11/2022 7:18:08 PM

Friday, February 11, 2022 7:18:08 PM

Post# of 447401
I’m only following MITIGATE because it’s using Vascepa and it’s an independent trial run by Kaiser ( I’m a CAD Kaiser patient )

The advantage of this trial is that it’s all “ in house “
Kaiser has a state of the art electronic tracking system
Roughly 40% of the Kaiser ASCVD patients they have asked to participate have signed on . That is a high number for clinical trials
This trial is well funded with a dedicated team monitoring compliance with the drug ( Vascepa ) being taken and collecting and analyzing the data .

THIS trial will tell us if Vascepa reduces the risk of hospitalization from Covid AND … in 2023 … if Vascepa reduces the risk of CV events in prior event patients … ie will it confirm R-IT risk reduction numbers for these subgroups via divergence of trial arms ( no V vs V ) after 1-2 yrs

Kiwi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News